ICON PLC
About ICON PLC
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $8.3B
- Net income
- $229.3M
- Total assets
- $16.3B
- Market cap
- $11.4B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $11.4B
- Shares outstanding
- 75.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 15, 1998
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $229.3M in FY2025.
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review ICON PLC.
Write a review
News about ICON PLC
News & sentiment via Polygon.io
